Status
Conditions
Treatments
About
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with rheumatoid arthritis must also meet the following enrollment criteria:
Patients with SLE will also be required to meet the following enrollment criteria:
Patients with dry syndrome were also required to meet the following enrollment criteria:
Patients with systemic sclerosis were also required to meet the following enrollment criteria:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
18 participants in 1 patient group
Loading...
Central trial contact
xiaojuan zhao, master; zhu chen, M.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal